BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Vaccines clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for vaccine: 430 (142 sponsors; 105 newly posted in the last 180 days, 9 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 26.7, rank 8 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 8, Phase 1 100, Phase 2 123, Phase 3 124, Phase 4 24, N/A 51.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pfizer PFE37NA 14, P4 1, P3 16, P2 3, P1 3119
GlaxoSmithKline31P3 14, P2 8, P1 6, NA 1, P4 2710
Sinovac Biotech Co., Ltd SVA20P4 4, P1 2, P3 10, P2 2, NA 269
Sanofi SNY22NA 3, P1 4, P2 5, P4 1, P3 995
Merck Sharp & Dohme LLC MRK10P1 1, P3 8, NA 111
CanSino Biologics Inc.14NA 4, P2 2, P4 1, P1 3, P3 452
Changchun BCHT Biotechnology Co.12P4 2, P1 5, P3 3, EARLY_P1 1, P2 132
Sanofi Pasteur, a Sanofi Company SNY10P2 6, P3 3, NA 104
Bavarian Nordic7P1 1, P2 3, P3 312
MAXVAX Biotechnology Limited Liability Company7P2 2, P3 3, P1 1, NA 110
Sinovac Life Sciences Co., Ltd.7P1 2, P3 3, P2 211
PT Bio Farma5P3 3, P1 1, NA 132
Takeda TAK5NA 2, P3 302
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd4P3 3, P1 100
ModernaTX, Inc.20NA 2, P1 7, P4 4, P2 5, P3 287
BioNTech SE BNTX8P2 2, P1 3, P4 1, P3 231
Sinovac (Dalian) Vaccine Technology Co., Ltd.5P4 3, P3 200
GC Biopharma Corp4P2 1, P3 2, P1 131
Shanghai Bovax Biotechnology Co., Ltd.4P3 2, NA 1, P2 101
Bharat Biotech International Limited3P2 1, P3 200
Inmunotek S.L. new entrant2P3 220
National Vaccine and Serum Institute, China2P3 200
Guangzhou Patronus Biotech Co., Ltd.8P1 5, P2 2, P3 120
Serum Institute of India Pvt. Ltd.6NA 2, P1 1, P3 1, P2 232
Suzhou Abogen Biosciences Co., Ltd.6P2 2, P3 1, P1 2, EARLY_P1 110

New-entrant sponsors: Inmunotek S.L..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-23 est.P3GlaxoSmithKlineNCT07596199 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenDiphtheria-Tetanus-acellular Pertussis Vaccinesactive not recruiting102
2026-11-28 est.P3Sanofi SNYNCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationYellow Fever Immunizationactive not recruiting2440
2026-12 est.P1/P2Dren BioNCT05475925 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasLGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary Crecruiting200
2026-12-01 est.P1/P2Sanofi SNYNCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain Pandemic Influenza Immunization; Healthy Volunteersactive not recruiting720
2027-01 est.P3Sinovac Biotech Co., Ltd SVANCT07505836 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsEpidemic Meningitis; Meningococcal Vaccinesrecruiting1040
2027-01-18 est.P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 YeaHuman Metapneumovirus Immunization; Respiratory Syncytial Virus Immunizationactive not recruiting1530
2027-02 est.P3PT Bio FarmaNCT07854847 Study Interchangeability Hep-B Vaccine Administered at Birth DoseVaccination Adverse Event; Immunogenicity, Vaccinenot yet recruiting270

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-10-01FDA AdComheldAdCom 2026-10-01: Vaccines and Related Biological Products Advisory Committee
2026-08-05PDUFA date (company-disclosed)date passedModerna, Inc. MRNAPDUFA August 5 - Moderna, Inc.
2026-06-18FDA AdComheldAdCom 2026-06-18: Vaccines and Related Biological Products Advisory Committee
2026-05-28FDA AdComheldAdCom 2026-05-28: Vaccines and Related Biological Products Advisory Committee
2026-03-12FDA AdComheldAdCom 2026-03-12: Vaccines and Related Biological Products Advisory Committee

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Sinovac Biotech Co., Ltd SVANCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsEpidemic Meningitis; Meningococcal Vaccinesactive not recruiting660
2026-09-20 est.P2/P3Bharat Biotech International LimitedNCT07555392 A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Active Immunisation for Chikungunya Virus Infectionrecruiting1000
2026-09-04P3GlaxoSmithKlineNCT07596173 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged Diphtheria-Tetanus-acellular Pertussis Vaccinescompleted90
2026-08-01 est.P3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT07473427 Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese ChildrenVaricella (Chickenpox); Varicella Immunisationnot yet recruiting300
2026-07-15 est.P3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT07475000 Second Dose of Varicella Vaccine in Healthy ChildrenVaricella (Chickenpox); Varicella Immunisationrecruiting300
2026-07-02P3Medigen Vaccine Biologics Corp.NCT07178522 A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 YearsEnterovirus 71 Inactivated Vaccineactive not recruiting379
2026-05-31 est.P1/P2Sinovac Biotech Co., Ltd SVANCT07400003 Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA VaccineHerpes Zoster; mRNA Vaccinerecruiting519

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "vaccine"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.